What NTx does

NTx (Nature's Toolbox, Inc.) is a private biotechnology company founded in 2015 and headquartered in Rio Rancho, New Mexico, that has built a proprietary continuous-flow, cell-free biomanufacturing platform for RNA (mRNA and saRNA) and protein synthesis. The flagship system, NTxscribe, is an automated benchtop bioreactor using proprietary hollow-fiber technology and single-use cartridges running on NTxbiomaterials reagents (manufactured in the U.S. with fully domestic raw materials) to produce 10–50 mg of high-integrity RNA in roughly three hours, with linear scalability from research to commercial volumes. NTxpress, the company's second platform, is described as the first fully recombinant cell-free protein expression system supporting both linear and circular DNA templates. A Cryo-EM service (Thermo Fisher Glacios 2 with Falcon 4i detector) and NTx Services for contract mRNA synthesis (5/10/25 mg packages, 2-week standard turnaround) round out the offering.

NTx monetizes through a hybrid hardware-plus-consumables model: NTxscribe benchtop systems sold to enterprise biopharma, biotech, and academic accounts, paired with recurring NTxbiomaterials cartridges and proprietary reagents, plus professional-services revenue from mRNA synthesis and Cryo-EM work. Distribution is direct via an enterprise field-sales motion targeting pharmaceutical/biotech firms, leading academic medical centers (early-access relationships with Mayo Clinic, Houston Methodist, and others), and government health agencies (notably BARDA under a DRIVe "Vaccines on Demand" contract). The company participates actively in flagship mRNA and immuno-oncology conferences (SITC, International mRNA Health Conference, Alliance for mRNA Medicines) and supports sales with content marketing including an NTxscribe whitepaper and a DNA Template Calculator.

The business is in early commercial stage following NTxscribe's full commercial launch in January 2025 and the launch of NTx Services in September 2024. Capital base is roughly $86 million across disclosed financings led by RA Capital Management ($47.5M Series B, Nov 2023), J.P. Morgan ($15M venture debt, Dec 2024), and Anzu Partners (early investor and board representation). The company is investing in capacity via a new $31 million Plano, Texas biomanufacturing facility (170+ jobs, Texas Enterprise Fund support, opening early 2026) and is preparing a Series C to transition NTxscribe from research-use-only to GMP clinical-grade manufacturing under recently installed CEO Dr. Joan Haab.

Name

NTx

Legal name

Nature's Toolbox, Inc.

Website

https://ntxbio.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

NTx is a private biotechnology company that builds automated, continuous-flow, cell-free biomanufacturing systems — led by the NTxscribe benchtop RNA platform and NTxpress protein platform — using proprietary hollow-fiber bioreactors and U.S.-made reagents, serving biopharmaceutical firms, academic medical centers, and government agencies such as BARDA.

Ownership category

akta.pro rank

Product category

Bioprocess Manufacturing Equipment

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

akta.pro primary industry

mRNA/LNP & Nucleic Acid Therapeutics CDMO (HLAGABAF)

Keywords

• Cell-free biomanufacturing
• RNA synthesis platforms
• MRNA manufacturing systems
• Protein expression technology
• Continuous flow bioreactors

Headquarters

HQ city

Rio Rancho

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. NTxscribe Hardware Systems: Sale of benchtop NTxscribe bioreactor systems for RNA manufacturing. The system is available for order through the company's website and is targeted at pharmaceutical companies, biotech firms, and research institutions requiring on-demand RNA production capability.
2. mRNA Synthesis Services: Contract manufacturing services using NTxscribe technology for mRNA synthesis. Services include standard packages of 5mg, 10mg, or 25mg with 2-week turnaround. Offers modified nucleotides (N1-methylpseudouridine), various cap options, and purification methods.
3. Cryo-EM Services: High-end cryo-electron microscopy services including sample optimization, image acquisition, data processing and 3D analysis, training, and consulting. New Mexico's only high-end Cryo-EM facility.
4. Proprietary Reagents (NTxbiomaterials): Single-use RNA cartridges and proprietary enzyme/reagent consumables that run on NTxscribe systems. Manufactured in the U.S. with domestic raw materials.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Core offering

NTx develops and sells automated, continuous-flow, cell-free biomanufacturing systems for RNA and protein synthesis. The flagship NTxscribe benchtop platform uses proprietary hollow fiber bioreactors and NTxbiomaterials reagents to produce 10-50mg of high-integrity mRNA/saRNA in 3 hours, while NTxpress is a fully recombinant cell-free protein expression platform. The company also offers contract mRNA synthesis services and Cryo-EM structural analysis services.

Product overview

NTx Bio offers a unified platform-plus-services portfolio centered on continuous-flow biomanufacturing technology for RNA and protein synthesis. The core offering consists of NTxscribe® (automated benchtop system for mRNA/saRNA synthesis) and NTxpress® (fully recombinant cell-free protein expression platform), both designed for scalable, high-quality output from research doses to commercial volumes. These platforms are complemented by mRNA Services (contract synthesis using NTxscribe® technology) and Cryo-EM Services (structural analysis). A DNA Template Calculator tool supports NTxscribe® users with reaction planning. The portfolio emphasizes domestically-sourced materials, push-button automation, and linear scalability from personalized medicine to pandemic-scale response.

Differentiator

Problem solved

Functional benefit

Brands

• NTxscribe®: Automated continuous flow RNA in vitro transcription (IVT) and purification system for producing high-integrity mRNA and saRNA on the benchtop
• NTxpress®
• NTxbiomaterials
• NTx Services

Products and services

• NTxscribe Automated, continuous-flow benchtop system for high-integrity mRNA and saRNA synthesis and purification. Uses proprietary hollow fiber bioreactors and NTxbiomaterials reagents to produce 10-50mg of purified RNA in 3 hours with push-button operation and linear scalability. Targets pharmaceutical companies, biotech firms, CDMOs, and research institutions needing on-demand RNA production.
• NTxpress

Quantifiable outcome

• Produces 10-50mg of high-integrity RNA in 3 hours (vs. days for traditional methods)
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Six partnerships are on record, tiered core and minor.

• BARDA DRIVecoreStrategic or Co-development Partner · 7 September 2023Vaccines on Demand contract awarded to demonstrate NTxscribe's capability for rapidly deployable RNA vaccine manufacturing. NTx collaborates with Houston Methodist Hospital to fulfill the need for rapid response manufacturing capability.
• Houston Methodist HospitalcoreStrategic or Co-development Partner · 7 September 2023Collaboration partner with NTx under BARDA DRIVe contract to demonstrate NTxscribe platform for RNA vaccine manufacturing. Dr. John Cooke's RNA Therapeutics Program utilizes NTx technology.
• City of PlanominorStrategic or Co-development PartnerPartnership with City of Plano for new biomanufacturing facility as part of North Texas life sciences hub development.
• Society for Immunotherapy of Cancer (SITC)minorChannel Partner/ Reseller/ DistributorExhibition and presence at SITC 2024 conference (Booth #747) to showcase NTxscribe platform to immunotherapy research community.
• International mRNA Health ConferenceminorChannel Partner/ Reseller/ DistributorExhibition presence at 12th International mRNA Health Conference (Booth #37) to engage with mRNA research and development community.
• Alliance for mRNA Medicines (AMM)minorStrategic or Co-development PartnerNTx team members participating in AMM 1st Annual Meeting as founding members of the Alliance for mRNA Medicines. Dr. Jeff Coller also serves on AMM's scientific advisory board.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Lonza Group: Lonza is one of the world's largest CDMOs offering mammalian, microbial, and cell/gene therapy manufacturing services, including mRNA and nucleic acid therapeutics. While much larger and more diversified than NTx, Lonza is a key reference competitor in the mRNA/biologics CDMO space NTx targets, with established GMP facilities and large pharma customer relationships.
• Catalent: Catalent is a major global CDMO offering biologics, cell/gene therapy, and nucleic acid manufacturing services, with extensive GMP capacity. While not exclusively focused on mRNA like NTx, Catalent competes for the same biopharma CDMO budgets and is an established incumbent in nucleic acid and vaccine manufacturing.
• Thermo Fisher Scientific: Thermo Fisher offers bioprocessing equipment, consumables, and CDMO services through its Patheon and BioProduction businesses, including nucleic acid and cell/gene therapy manufacturing. As a broad life sciences tools and services incumbent, Thermo Fisher competes both as a CDMO and as a supplier of bioprocessing infrastructure that NTx customers could alternatively use.

Direct peers

• Aldevron: Aldevron (now part of Danaher) is a CDMO specializing in plasmid DNA, mRNA, and recombinant proteins for cell and gene therapies and vaccines. Aldevron is one of the closest direct competitors to NTx in the nucleic acid CDMO space, with comparable focus on mRNA synthesis services for therapeutic developers.
• TriLink BioTechnologies (Maravai LifeSciences): TriLink is a CDMO specializing in mRNA synthesis, oligonucleotide manufacturing, and cleanCap mRNA capping reagents. As a direct nucleic acid manufacturing peer with strong mRNA focus and a broad biopharma customer base, TriLink is one of NTx's most directly comparable competitors in mRNA CDMO services.

Emerging players

• CureVac: CureVac is an mRNA technology company developing prophylactic vaccines, cancer therapies, and molecular therapies, with significant internal manufacturing capabilities and proprietary TheRNA technology. While primarily a therapeutic developer rather than a CDMO, CureVac represents a competing mRNA platform approach and could either partner with or compete against NTx's positioning.
• Ginkgo Bioworks: Ginkgo Bioworks is a synthetic biology platform company offering cell engineering and biomanufacturing services across multiple end markets including pharma and agriculture. While broader than NTx, Ginkgo competes in the programmable biology/biomanufacturing services space and represents an alternative platform for customers seeking outsourced bio-production capabilities.

Others

• Cytiva: Cytiva is a Danaher-owned life sciences tools and bioprocessing company providing equipment, consumables, and services for biologic and vaccine manufacturing. Cytiva is not a direct CDMO competitor but supplies bioprocessing infrastructure (bioreactors, chromatography, single-use systems) that NTx customers and competitors alike purchase, making it an important ecosystem reference point.
• BioNTech: BioNTech is a leading mRNA therapeutics company with substantial internal manufacturing capacity and platform technology, including its BioNTainer modular manufacturing approach. While BioNTech is primarily a therapeutic developer rather than a CDMO customer, its insourcing of mRNA manufacturing reduces the addressable outsourced market NTx targets.

Regional players

• Atara Biotherapeutics: Atara is a cell and gene therapy company with proprietary allogeneic T-cell and next-generation platform manufacturing capabilities, including in-house viral vector and cell therapy manufacturing. While focused on cell therapy rather than mRNA, Atara represents a comparable US-based therapeutic platform investing in proprietary manufacturing and could be a customer or competitor depending on modality evolution.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/ntxbio
• Xx.com/NaturesToolbox_

Revenue estimate

Valuation estimate

Number of profiles

Profiles19 records

Funding overview

Funding rounds5 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NTx